Baby G.E.M. (genetics, environment, microbiome) study

aims to establish a cohort of infants born to mothers with IBD, and collect data and samples from birth, so that we may be able to better understand early risk factors for IBD.


The MOM MII (Maternal Offspring Microbiome, Metabolomic, and Immunologic profiling in IBD) study

was initiated in 2015 with the aims to investigate the impact of pregnancy on maternal IBD, and the impact of maternal IBD and therapies on neonatal outcomes and the infant’s future health during childhood.

MOM MII studies include the following

a) Maternal immunosuppressive IBD medications may result in neonatal immune dysregulation.  (Co-investigator Dr. S. Elahi, funding from WCHRI Innovation grant): We are investigating the immune profile of pregnant women with IBD and the immune profile of the neonate at birth.  This will give clinicians and scientists a better understanding of the impact of maternal IBD disease, disease activity, and IBD therapies, on the fetus and neonate.

b) Cytokine profiling in women with IBD during pregnancy: We are studying the changes in pro-inflammatory and anti-inflammatory cytokines during pregnancy and post partum in women with IBD and healthy volunteers.  A better understanding of the complex interactions between pregnancy and IBD will help guide management of IBD in pregnancy.

c) Influence of Maternal IBD on Neonatal Gut Microbiome: Determining if Our Mothers are Responsible for our Dysbiotic Microbiome and Subsequent IBD (co-investigator Dr. K Madsen, funding from FLIBD grant): Breast milk contains many healthy components such as nutrients, antibodies, fats, oligosaccharides, and bacteria, which help the infant establish their microbiome.  We are studying how IBD and IBD therapies may affect breast milk composition, and whether this then affects the infants.

d) Urine and serum metabolomics to predict IBD disease activity in pregnancy. (co-investigators Dr. Madsen, Dr. Fedorak, Dr. Dieleman, funding from Clinical  Research and Progress (CRAP) grant, CEGIIR): Through urine and serum metabolomic profiling of both pregnant IBD women and pregnant control (non IBD) women, we hope to analyze any differences between metabolites produced during preconception through T3 that could be used as indicators of flaring, remission, or adverse fetal outcomes.